Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept
Farge D, Loisel S, Resche-Rigon M, Lansiaux P, Colmegna I, Langlais D, Catney C, Pugnet G, Thibault A, Maria J, Chatelus E, Martin T, Hachulla E, Kheav VD, Lambert N, Wang HC, Michonneau D, Martinaud C, Sensebé L, Tarte K.
The Lancet Rheum. 2022 FEB 4(2)91-104. doi: 10.1016/S2665-9913(21)00326-X. IF 8.1
Farge et al. 2022.pdf
Adobe Acrobat Document
900.2 KB